Express Pharma

Roche launches new treatment options for women with metastatic breast cancer in India


New personalised medicines offer increased survival benefit and improved quality of life to Indian women with aggressive HER2-positive form of metastatic breast cancer

Roche Pharma India has launched two innovative medicines for the treatment of HER2-positive metastatic breast cancer, a particularly aggressive form of the disease. The new drugs, Perjeta and Kadcyla, have been shown to both extend survival and improve quality of life in their approved applications for metastatic HER2-positive breast cancer. Perjeta is approved in combination with trastuzumab (Herclon) and docetaxel chemotherapy for people with previously untreated HER2-positive metastatic breast disease (first-line treatment). Kadcyla is approved for people with HER2-positive metastatic breast disease previously treated with trastuzumab (Herclon) and taxane chemotherapy (second-line treatment).

“The introduction of these therapies is a significant milestone in the treatment of HER2-positive metastatic breast cancer in India and reaffirms our commitment to bring Roche’s innovative medicines to patients in India as quickly as possible,” said Maturin Tchoumi, Managing Director, Roche Pharma India.

“These targeted medicines represent a completely new way to treat HER2-positive metastatic breast cancer, with which we aim to help women in India live as long and as well as possible.”

With its targeted breast cancer medicine Herclon (globally known as Herceptin), Roche has helped transform the treatment of HER2-positive breast cancer over the last several years in India. Recognizing the need for additional treatment options, Roche is aiming to introduce a new standard of care for HER2-positive metastatic breast cancer patients in India with Kadcyla and Perjeta.

Comments are closed.